Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13681861 | 0.99 | TRPV1 (0.50) | TRPV1HTR7 | |
| SCHEMBL13038406 | 0.89 | CYP3A4 (0.53) | TRPV1HTR7 | |
| SCHEMBL13038367 | 0.88 | MC4R (0.45) | HTR7 | |
| SCHEMBL13038057 | 0.85 | ACHE (0.48) | HTR7 | |
| SCHEMBL13038380 | 0.85 | KDM4E (0.48) | TRPV1 | |
| SCHEMBL13038379 | 0.85 | SIGMAR1 (0.45) | — | |
| SCHEMBL13037429 | 0.84 | KDM4E (0.47) | — | |
| SCHEMBL13038455 | 0.84 | TRPV1 (0.37) | TRPV1HTR7 | |
| SCHEMBL13038486 | 0.84 | ALDH1A1 (0.48) | TRPV1HTR7 | |
| SCHEMBL13681865 | 0.83 | MAOA (0.40) | TRPV1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311499-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-21 | — | — | EP | claimed |
| WO-2002012224-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-7855198-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1311499-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002012224-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885HTR7 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.